Chinese State-Owned Funds Invest in Biotech Firm MabPlex

MabPlex International, a Chinese biologics development and manufacturing solutions provider, has completed a RMB400 million (US$59.1 million) series A round of financing. The round was led by China’s state-owned SDIC Venture Capital and Shenzhen Capital Group, an investment unit of Shenzhen Municipal Government, according to an announcement today.

China Money Network

Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Register Now

Want to read this important story?

Access thousands of news articles and data posts over the past 9 years!

Already have an account or paid subscription? Log in

Caishen.Co - Primary Data for China Secondary Investment and Stock Markets